Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum
February 13, 2025 19:40 ET
|
Oculis Holding AG
ZUG, Sviss, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknilyfjafyrirtæki með áherslu á nýsköpun til að meðhöndla...
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
February 13, 2025 19:40 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
February 13, 2025 19:39 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
February 07, 2025 18:35 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
...
Oculis updates share capital for its existing at-the-market offering program
January 31, 2025 16:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares...
Oculis Publishes Notification of Major Changes in Voting Rights
January 21, 2025 16:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights.
Attachment
Notification of Major Changes in Voting...
Oculis Publishes Notification of Major Changes in Voting Rights
January 20, 2025 17:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights.
Attachment
Notification of Major Changes in Voting...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
January 06, 2025 03:53 ET
|
Oculis Holding AG
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential...
Oculis tilkynnir um jákvæðar niðurstöður úr fasa 2 ACUITY rannsóknar á OCS-05 við sjóntaugabólgu; aðalviðmiði um öryggi náð auk lykilviðmiða um virkni sem opnar á þróun sem mögulegt fyrsta lyf sinnar tegundar á sviði taugaverndandi meðferða
January 06, 2025 03:47 ET
|
Oculis Holding AG
ZUG, Sviss, Jan. 06, 2025 (GLOBE NEWSWIRE) -- OCS-05 var öruggt og þoldist vel í samanburði við lyfleysu.Tölfræðilega marktækar framfarir á virkni samanborið við lyfleysu, m.a. fyrir þykkt sjónhimnu...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
January 06, 2025 03:47 ET
|
Oculis Holding AG
ZUG, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) -- OCS-05 showed a favorable safety and tolerability profile compared to placeboAchieved statistically significant results on key secondary efficacy...